**Goldman Sachs** maintains a neutral perspective on **Viatris (VTRS)** with a $10 price target, implying some investors should hold onto the stock. Viatris displayed steady reports for Q1 2025 and reaffirmed its outlook for the year. The company delivered positive results from its second Phase 3 VEGA-3 trial for MR-141 in Presbyopia, indicating promising performance. However, some critique exists over the company's business model. Despite this, deep analysis of the stock considers a 22.18% potential upside midst strong cash flow and high dividend yield. Viatris also faced a securities fraud class action due to an FDA inspection fallout. Studies revealed MR-142's potential in improving visual disturbances under mesopic, low-contrast conditions, based on the positive results of the LYNX-2 trial. Despite turbulence, Viatris has shown notable certainty with the CEO buying stocks in a large sum, signaling confidence. Additionally, Viatris's forthcoming presentation at Barclays 27th Annual Global Healthcare Conference is expected to contribute valuable insights for investors. Finally, Viatris aims to report its Q2 2025 financial results on August 7, 2025, which could potentially pivot its financial standing.
Viatris VTRS News Analytics from Wed, 28 Feb 2024 08:00:00 GMT to Sat, 12 Jul 2025 18:54:33 GMT - Rating 1 - Innovation 3 - Information 4 - Rumor -7
